NCT02221180View on ClinicalTrials.gov

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Bioequivalence
Interventions
DRUG

Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]

Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.

DRUG

Canagliflozin

Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.

DRUG

Metformin

Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.

Trial Locations (1)

Unknown

Lincoln

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02221180 - Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants | Biotech Hunter | Biotech Hunter